Table 1.
List of approved and under clinical trial cancer immunotherapies.
| Type | Name (trade name) |
Manufacturer/ CTid |
Target/ Platform |
Indication (Phase) |
|---|---|---|---|---|
| Cytokines | IFN-α2b (Intron A) | Merck & Co., Inc | Kaposi Sarcoma (II), leukemia (IV), lymphoma (IV), melanoma (III) | |
| IFN-α2a (Roferon-A) | Genentech, Inc. | Kaposi Sarcoma (II), leukemia (IV) | ||
| Recombinant IL-2 (Aldesleukin) | Novartis | RCC (III), melanoma (III) | ||
| 1-isobutyl-1H-imidazo (Imiquimod) | Perrigo | Superficial basal cell carcinoma (III) | ||
| IFN-α2b | NCT02634294 | Hematological malignancies (II/III) | ||
| IFN-α2a | NCT03253250 | Hepatocellular carcinoma (IV) | ||
| NCT02829775 | Advanced tumors (II/III) | |||
| GM-CSF | NCT03363373 | Neuroblastoma (II) | ||
| Checkpoint inhibitors | Ipilimumab (Yervoy) | Bristol-Myers Squibb | CTLA-4 | Melanoma (IV) |
| Pembrolizumab (Keytmda) | Merck & Co | PD-1 | HL (III), lung cancer (IV), melanoma (IV), head and neck cancer (IV), stomach cancer (III) | |
| Nivolumab (Opdivo) | Bristol-Myers Squibb | PD-1 | Melanoma (IV), RCC (IV), HL (III), liver cancer (IV), bladder cancer (III), NSCLC (IV) | |
| Atezolizumab (Tecentriq) | Roche, Genentech | PD-1 | Lung (IV), breast (III), bladder (III), urinary tract cancer (III) | |
| Avelumab (Bavencio) | Merck KGaA and Pfizer | PD-L1 | Merkel cell carcinoma (III) | |
| Durvalumab (Imfinzi) | Medimmune/AstraZe neca | PD-L1 | Bladder (III), urinary tract cancer (III), NSCLC (IV) | |
| Cemiplimab | Sanofi | PD-L1 | Squamous cell carcinoma (III) | |
| IMP321 | NCT00365937, NCT01308294, NCT02614833, NCT03625323 | LAG-3 | Advanced melanoma (I/II), Metastatic breast cancer (II), Advanced NSCLC and HNSCC (II), | |
| Relatlimab | NCT01968109, NCT02488759, NCT02061761, NCT03459222, NCT03623854, NCT03743766, NCT03642067, NCT03607890, NCT02996110, NCT02935634, NCT02750514, NCT02060188, NCT02519322 | LAG-3 | Virus associated cancer (I/II), hematologic malignancies (I/II), Advanced solid tumors (II), chordoma (II), melanoma (II), RCC (II), GC (II), NSCLC (II), CRC (II), | |
| LAG525 | NCT02460224, NCT03365791, NCT03499899, NCT03484923 | LAG-3 | Advanced Solid tumor (I/II), hematological malignancies (II), TNBC (II), melanoma (II) | |
| MK-4280 | NCT03598608, NCT03516981 | LAG-3 | Advanced NSCLC (II), hematological malignancies (I/II), | |
| BI754111 | NCT03697304 | LAG-3 | Advanced solid tumor (II) | |
| TSR-022 | NCT03680508 | TIM-3 | Liver Cancer (II) | |
| MBG453 | NCT02608268 | TIM-3 | Advanced malignancies (I/II) | |
| BMS-986258 | NCT03446040 | TIM-3 | Advanced solid tumor (I/II) | |
| Tiragolumab | NCT03563716 | TIGIT | Advanced NSCLC (II) | |
| BMS-986207 | NCT02913313 | TIGIT | Advanced solid tumor (I/II) | |
| Enoblituzumab | NCT02923180 | B7-H3 | Prostate cancer (II) | |
| 131I-8H9/omburtamab | NCT03275402 | B7-H3 | Neuroblastoma/leptomeningeal metastases (II/III) | |
| CAR-T cells | Tisagenlecleucel (Kymriah) | Novartis Pharma | CD19 | Leukemia (III), lymphoma (III) |
| Axicabtagene ciloleucel (Yescarta) | Kite Pharma | CD19 | NHL (II) | |
| NCT03631576, NCT02937103, NCT03398967 | CD123 | AML (II/III), myeloid malignancies (I/II) | ||
| NCT03398967 | CD19 and CD20 or CD22 | B cell leukemia and lymphoma (I/II) | ||
| NCT02958397 | CD33 | myeloid malignancies (I/II) | ||
| NCT03754764 | CD38 | B-ALL (I/II) | ||
| NCT03196414 | CART-138 | MM (I/II) | ||
| NCT03778346 | CD38/CD138 | MM (I) | ||
| NCT03767751 | Dual CD38/BCMA | MM (I/II) | ||
| NCT03222674 | Muc1/CLL1/CD33/CD38/CD56/CD123 | AML (I/II) | ||
| Vaccine | Spiuleucel-T (Provenge) | Dendreon Pharmaceuticals | Autologous immuno therapy | Hormone-refractory prostate cancer (III) |
| BCG | Merck & Co., Dianon Systems, Evans Vaccines, Statens Serum Institut, Japan BCG Laboratory NCT03300843 | Attenuated Mycobac terium bovis DC | Bladder cancer (IV) solid cancers (II) | |
| NCT03480152 | RNA | solid cancers (I/II) | ||
| NCT03598816 | DNA | RCC (II) | ||
| NCT03633110 | Synthetic peptide | Solid cancers (I/II) | ||
| NCT03639714 | RNA | Solid cancer (I/II) |
Abbreviation: Bacillus Calmette Guerin (BCG), acute myeloid leukemia (AML), multiple myeloma (MM), renal cell carcinoma (RCC), B-cell acute lymphoblastic leukemia (B-ALL), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), gastric cancer (GC), colorectal cancer (CRC), head and neck squamous cell cancer (HNSCC), Hodgkin lymphoma (HL), non - Hodgkin lymphoma (NHL)